Patient-derived colorectal microtumors predict response to anti-PD-1 therapy.
Saved in:
| Title: | Patient-derived colorectal microtumors predict response to anti-PD-1 therapy. |
|---|---|
| Authors: | Nguyen DT; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Schaller MA; Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, United States., Terracina KP; Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, United States., Xu X; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Pedro DI; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Pepe A; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Urueña JM; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Dupee Z; Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, United States., Diodati N; Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, United States., Smolchek RA; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Famiglietti JE; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Nguyen NTY; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States., Tushoski-Alemán GW; Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, United States., Cheng K; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Chen L; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Linn D; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Vidimar V; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Fatima A; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Kwon SW; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Sun D; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Chen H; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Xu H; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Long B; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Moy LY; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Howell BJ; Department of Quantitative Biosciences, Merck & Co., Inc., Rahway, NJ, United States., Addona GH; MRL, Discovery, Preclinical and Translational Medicine, Merck & Co., Inc., Rahway, NJ, United States., Sawyer WG; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, FL, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Aug 12; Vol. 16, pp. 1640500. Date of Electronic Publication: 2025 Aug 12 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1640500 |
